Press coverage about Arsanis (NASDAQ:ASNS) has been trending somewhat negative recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arsanis earned a news impact score of -0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.4019086324316 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Arsanis traded down $0.01, reaching $2.26, on Friday, MarketBeat reports. 65,762 shares of the company’s stock were exchanged, compared to its average volume of 142,359. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.38 and a quick ratio of 7.38. The firm has a market capitalization of $32.45 million and a PE ratio of -0.14. Arsanis has a twelve month low of $2.08 and a twelve month high of $28.69.
Arsanis (NASDAQ:ASNS) last posted its earnings results on Thursday, May 10th. The company reported ($0.74) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.04) by $0.30. equities research analysts expect that Arsanis will post -3.38 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the company. Zacks Investment Research lowered Arsanis from a “buy” rating to a “hold” rating in a report on Tuesday, May 15th. Cantor Fitzgerald set a $26.00 price objective on Arsanis and gave the stock a “buy” rating in a report on Thursday, May 10th. ValuEngine raised Arsanis from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Piper Jaffray Companies lowered Arsanis from an “overweight” rating to a “neutral” rating in a report on Thursday, June 28th. Finally, Citigroup lowered Arsanis from a “buy” rating to a “neutral” rating in a report on Monday, July 9th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Arsanis currently has a consensus rating of “Hold” and an average target price of $20.00.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: Google Finance Portfolio
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.